Program

KEYNOTE SESSION

7:00 p.m.-8:30 p.m.

Targeting the Cancer Initiating Cell through Pharmacological Modulation of Aberrant PTEN/AKT/TOR Signaling
Pier Paolo Pandolfi, Harvard Medical School, Boston, MA

Feedback and Redundancy in the PI3K Signaling Pathway: Basic and Clinical Implications
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

OPENING RECEPTION

8:30 p.m.-9:30 p.m.

SESSION 1: MOUSE CANCER MODELS FOR THE PI3-KINASE/PTEN PATHWAY

8:00 a.m.-10:00 a.m.

Signaling by Isoforms of PI3-Kinase
Bart Vanhaesebroek, University of London, London, United Kingdom 

PI3-Kinase Signaling in Ras-driven Tumorigenesis
Julian Downward, Cancer Research UK London Research Institute, London, United Kingdom

PTEN, Stem Cells, and Tumorigenesis
Hong Wu, University of California, Los Angeles, CA

Targeting Class IA PI3K Isoforms in Cancer in Mouse Models
Jean J. Zhao, Dana-Farber Cancer Institute, Boston, MA

SESSION 2: ROLE OF THE PI3-KINASE PATHWAY IN HUMAN CANCERS

10:30 a.m.-12:30 p.m. 

PTEN and Other PI3K Pathway Changes in Cancer of the Breast
Ramon Parsons, Columbia University, New York, NY 

Regulation of PI3K Signaling: The Cornerstone of Sensitivity and Resistance to RTK Directed Therapies
Jeffrey A. Engelman, Harvard Medical School, Boston, MA

PI3K Pathway and Resistance to ErbB Receptor Antagonists
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

Targeting PI3K in Melanoma-Profile Matters
Matthias Wymann, Institute of Biochemistry and Genetics, Basel, Switzerland

POSTER SESSION / LUNCH

12:30 p.m.-3:00 p.m.

SESSION 3: BIOCHEMISTRY AND CELL BIOLOGY OF THE PI3-KINASE SIGNALING PATHWAY

3:15 p.m.-5:15 p.m.

PHiPPing the Switch to Growth Factor Signaling
Alexandra Newton, University of California, San Diego, CA

Biomarkers and the PI3K Pathway
George V. Thomas, University of California, Los Angeles, CA

Signaling by mTORC1 and mTORC2
David M. Sabatini, Whitehead Institute for Biomedical Research, Cambridge, MA

PTEN, PI3-Kinase, and Epithelial Polarity
Peter Downes, University of Dundee, Dundee, Scotland

SESSION 4: PREDICTING PATIENT RESPONSE TO PI3-KINASE PATHWAY INHIBITORS

8:00 a.m.-10:00 a.m.

Gene Expression-Based Diagnostics
Todd R. Golub, Broad Institute of MIT and Harvard University, Cambridge, MA 

Quantitative Tissue Analysis of Activation of the PI3K Pathway
Massimo Loda, Dana-Farber Cancer Institute, Boston, MA

Title to be announced
Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY

Biomarkers of PI3K Inhibitor GDC-0941
Lori S. Friedman, Genentech, Inc., South San Francisco, CA

SESSION 5: HOT TOPICS

10:30 a.m.-12:30 p.m. 

This exciting session will feature presentations from proffered abstracts and late-breaking papers. Please visit the conference website in early Fall for updates on speakers and the newest research that will be featured.

SESSION 6: PI3-KINASE PATHWAY INHIBITORS AND DESIGN OF CLINICAL TRIALS I

2:30 p.m.-5:00 p.m.

Discovery and Development of XL147 and XL765, Novel Inhibitors of the PI3K Pathway
Peter Lamb, Exelixis, San Francisco, CA

Development of Novel Inhibitors of the PI3K Pathway
Nancy E. Kohl, Merck Research Laboratories, Boston, MA

Targeting PI3K in Multiple Myeloma
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

GSK615: A Novel Inhibitor of Phosphoinositide 3-Kinase for the Treatment of Cancer
Kurt R. Auger, GlaxoSmithKline, Collegeville, PA

AKT-independent Signaling Downstream of Oncogenic PI3-Kinase in Human Cancer
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

POSTER SESSION / RECEPTION

5:00 p.m.-7:00 p.m.

SESSION 7: PI3-KINASE PATHWAY INHIBITORS AND DESIGN OF CLINICAL TRIALS II

8:00 a.m.-11:30 a.m.

Lessons from Sarcomas and Other Genomically Simple Diseases for Development of Signaling Pathway Inhibitors
George D. Demetri, Dana-Farber Cancer Institute, Boston, MA

Preclinical and Clinical Experiences with the Targeted PI3-Kinase Inhibitor SF1126
Ullrich S. Schwertschlag, Semafore Pharma, Indianapolis, IN

Targeting the PI3-Kinase Pathway in Glioblastoma
Ingo K. Mellinghoff, Memorial Sloan-Kettering Cancer Center, New York, NY

Targeting PI3K P110 Delta and Gamma for the Treatment of Cancer and Inflammation
Neill Giese, Calistoga Pharmaceuticals, Seattle, WA

PI3-K Signaling Studies in Cell Culture Models of Epithelial Cancers
Joan S. Brugge, Harvard Medical School, Boston, MA

NVP-BEZ235: A Dual PI3K/mTOR Inhibitor for Cancer Treatment
Michel Maira, Novartis Pharma AG, Basel, Switzerland

DEPARTURE